Article
UPDATED: Biogen spotlights a pair of painful pipeline setbacks as aducanumab showdown looms at the
Rating:
0.0
Views:
148
Likes:
1
Library:
1
Biogen has flagged a pair of setbacks in the pipeline, spotlighting the final failure for a one-time top MS prospect while scrapping a gene therapy for SMA after the IND was put on hold due to toxicity. Both failures will raise the stakes even higher on aducanumab, the Alzheimer's drug
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value